HRMY

Harmony BiosciencesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$49.00

Analysis reference price unavailable

Analysis 2026-10-24 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$39.00

Analysis reference price unavailable

Analysis 2026-10-24 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$26.00

Analysis reference price unavailable

Analysis 2026-10-24 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-24

AI commentary

Company-source operating evidence is constructive, but the leadership change tempers conviction. The packet's price anchors fell from $38.27 on October 15 to $36.13 on October 23, about 5.6%; those anchors alone do not establish the cause. The stored earnings-document row is chiefly about Editas and is not an official Harmony earnings release. Reliable post-transition analyst revisions, social coverage, options skew, short interest, and employee readings were not supplied; zero-valued sentiment fields mean unavailable, not neutral.

RankAlpha Sentiment Codex - 2026-10-24

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventBP-205 multiple-ascending-dose dataHigh impact

Harmony says Phase 1 multiple-ascending-dose data remain on track for Q4 2026. Results may change confidence in BP-205's development prospects, but clinical efficacy remains unproven [#SEC-8K-2026-08-04] [#8-K-2026-10-13].

2026-12-31catalystWAKIX revenue versus 2026 guidanceMedium impact

Q2 WAKIX revenue reached $261.3 million, up 30% year over year, and estimated average patients rose to 8,950. Delivery against reiterated full-year revenue guidance of $1.0 billion–$1.04 billion is the near-term commercial test [#SEC-8K-2026-08-04] [#8-K-2026-10-13].

2027-01-01eventCEO successionMedium impact

Peter Anastasiou is scheduled to succeed Jeffrey Dayno as CEO on January 1, 2027. Harmony reiterated revenue guidance and BP-205 timing alongside the announcement, but execution continuity still needs to be demonstrated [#8-K-2026-10-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-24 • Updated nightlySource: Internal modelMethodology